You can buy or sell Ophthotech and other stocks, options, ETFs, and crypto commission-free!
Ophthotech Corporation Common Stock, also called Ophthotech, is a biopharmaceutical company which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. Read More The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.
New York, New York
52 Week High
52 Week Low
Associated PressMar 6
Ophthotech to Present at the Cowen and Company 39th Annual Health Care Conference
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation. NEW YORK--(BUSINESS WIRE)--Mar 6, 2019--Ophthotech Corporation (Nasdaq: OPHT) announced today that Kourous A. Rezaei, M.D., Chief Medical Officer of Ophthotech, will present an overview of the Company at the Cowen and Company 39...
Simply Wall StFeb 27
Some Ophthotech Shareholders Have Copped A 97% Share Price Wipe Out
Ophthotech Corporation (NASDAQ:OPHT) shareholders should be happy to see the share price up 14% in the last month. But only the myopic could ignore the astounding decline over three years. Indeed, the share price is down a whopping 97% in the last three years. So it’s about time shareholders saw some gains. Only time will tell if the company can sustain the turnaround. While a drop like that is definitely a body blow, money isn’t as important as health and happiness. Check out our latest analysis for Opht...
Expected May 8, Pre-Market